Page 2 - பால் லிம்பர்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
MADISON, Wis., Jan. 12, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in
Cancer Prevention Research, a Journal of the American Association for Cancer Research, that expands on foundational clinical study findings to include a key younger population. Study results show that among average-risk adults between the ages of 45 and 49 Cologuard® (mt-sD­­­­NA) demonstrated test specificity of 95.2% in participants with non-advanced precancerous lesions or negative findings at colonoscopy and 96.3% in only those with negative colonoscopy findings. These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population. ­­­­­ ....

United States , Paul Limburg , Cara Connelly , Kevin Conroy , Megan Jones , Sciences Corp , Sciences On Facebook , Sciences On Twitter Exactsciences , Exchange Commission , United States Preventive Services Task Force , American Cancer Society , Screening At Exact Sciences , National Comprehensive Cancer Network , Us Preventive Services Task , Chief Medical Officer , Relations Contact , Exact Sciences , Exact Science , New England Journal , Services Task Force , Risk Factors , Annual Report , Quarterly Reports , Exact Sciences Corp , ஒன்றுபட்டது மாநிலங்களில் , பால் லிம்பர்க் ,